Beta Bionics shares exploded higher during the regular session despite a wave of negative news regarding a securities class action lawsuit filed against the company. Multiple law firms issued alerts throughout September 14 and 15 regarding the litigation, which alleges that the company misled investors about the safety and efficacy of its iLet insulin pump by failing to disclose over 18,000 customer complaints. While the lawsuit highlights a prior period where the stock plummeted over 37% due to these disclosures, the market ignored the negative sentiment today, pushing the shares up significantly to trade well above their 50-day moving average.